A Pragmatic Randomized Feasibility Trial of Influenza Vaccines
We conducted a pragmatic, open-label, active-controlled, randomized feasibility trial in Danish citizens aged 65 to 79 years during the 2021–2022 influenza season.
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
The global surge in the omicron (B.1.1.529) variant has resulted in many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination).
Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19
SARS-CoV-2 infection is clinically heterogeneous, ranging from asymptomatic to deadly.
Two-Years Follow-Up of Symptoms and Return to Work in Complex Post-COVID-19 Patients
Many COVID-19 patients present with severe long-lasting symptoms. They might benefit from a coordination team to manage such complex situations, but late efficacy still needs to be determined.
Pharmacists are encouraged to speak to members of their community about getting both the flu and COVID-19 vaccines at the same time
This 2022-23 flu season in the Northern Hemisphere arrived earlier than expected and we are also seeing a concerning increase in the number of respiratory syncytial virus (RSV) cases.
Stopping epidemics when and where they occur
Governments and the global community must urgently tackle difficult questions about why, how, where, and when diagnostics, treatments, and vaccines are produced, and about who is in control of their availability and distribution.
SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs
The first step in SARS-CoV-2 genomic surveillance is testing to identify people who are infected. However, global testing rates are falling as we emerge from the acute health emergency and remain low in many low- and middle-income countries.
|
ESWI Airborne: Meet the Members
Universal flu vaccines – soon a reality?
How close are we to a universal flu vaccine? Are universal corona vaccines attainable? What are some of the main challenges facing scientists in their quest to develop these vaccines?
News
Partner Organisations
Vaccination of special-risk groups: A toolkit for pharmacists by the International Pharmaceutical Federation (FIP)
It summarises key information, practice guidelines and additional resources in a very practical manner. The Influenza Diabetes Community (IDC) has contributed to the chapter on people living with diabetes.
News
Policy & Recommendations
Presidency Statement on the Coordination of COVID-19 Travel Measures
On 4 January, the Member States of the EU, in the presence of the Schengen Associated Countries, met in the framework of the Integrated Political Crisis Response (IPCR) to discuss the epidemiological situation in the EU/EEA and developments in China.
Policy & Recommendations
News
Impact of surge in China COVID-19 cases on epidemiological situation in EU/EEA
ECDC, together with the EU/EEA Member States and the European Commission has increased its monitoring activities and will revise risk assessments and adjust actions if needed.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.
